Home Self Admin denied as duplicate or overlapping therapy by Humana?

Humana's specific coverage criteria for home self admin are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Home Self-Administration as Duplicate Therapy — and How to Appeal

A duplicate-therapy denial on home self-administration typically means Humana's claims system flagged that the patient is already receiving the same drug or a drug in the same therapeutic class through a different delivery channel — most commonly in-office infusion or an infusion center — and the plan is declining to cover a separate home supply. The key question in every duplicate-therapy appeal is whether the two claims actually represent the same clinical service or whether the home administration route is a distinct, medically necessary component of care.

### Why This Denial Is Appealable

Duplicate-therapy denials are often automated flags, not individualized clinical reviews. If the prescriber has transitioned the patient from facility-based administration to home self-administration — a common and guideline-supported transition for stable patients — the prior facility claim may simply be a historical record, not a concurrent service. The appeal should demonstrate that the services are not actually duplicative and that home administration is independently medically justified.

### Federal Appeal Rights

• Internal appeal: File within the timeframe specified on the denial notice. For standard pre-service or post-service appeals Humana must respond within the regulatory timeframe noted in your Summary Plan Description.
• External review (ACA §2719 / ERISA §503): You retain the right to an independent external review after exhausting internal appeals, generally within four months of the final internal denial.
• Expedited review: Request this if a delay would seriously jeopardize health or your ability to regain maximum function.

### Documentation to Gather

1. Timeline of care: A clear chronology showing when facility-based administration ended (or will end) and when home self-administration begins, demonstrating the two services do not overlap. 2. Prescriber transition letter: A letter from the treating physician explaining the clinical rationale for transitioning to home self-administration — for example, clinical stability, reduced infection risk from repeated facility visits, or improved adherence — and confirming that facility-based infusion is not being billed concurrently. 3. Training documentation: Records showing the patient received home self-administration training, supporting readiness and clinical appropriateness. 4. Claim reconciliation: If the duplicate flag was triggered by a billing overlap, request an explanation of benefits (EOB) and have the prescriber's billing office confirm whether the facility claim is historical or concurrent. 5. Clinical notes: Chart notes documenting the patient's current clinical status and the prescriber's decision to move to home administration.

### Criteria-Mapping Structure

Review Humana's published coverage policy for home self-administration of the relevant drug. Map each coverage requirement — including any requirement that facility-based administration has been completed or is not concurrent — to the specific chart and billing evidence. State explicitly that this is a transition, not a duplication, and cite the prescriber's medical judgment.

Confirm the exact coverage criteria and any billing rules with Humana's current published policy and the FDA-approved prescribing label for the drug in question.